Jan

2012

Aviir, Inc.: Series E $10M

Posted in I - Series E, Q - 4Q11, R - WEST, X - Cardiology, X - Device (Diagnostic), X - Metabolism, XX - CA

Aviir (Irvine, CA) a commercial-stage diagnostic company focused on pharmacogenomic and genetic tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders, closed a $10M Series E financing. Participants include Merck Global Health Innovation, Bay City Capital, Aberdare Ventures and New Leaf Venture Partners.

Sep

2011

CardioKinetix, Inc.: Series E $44M

Posted in I - Series E, Q - 3Q11, R - WEST, X - Device (Cardiology), X - Device (Catheter), XX - CA

CardioKinetix (Redwood City, CA) a clinical-stage medical device company focused on transcatheter implants for congestive heart failure, closed a $44M Series E financing. Participants include SV Life Sciences, New Leaf Venture Partners, U.S. Venture Partners, J.P. Morgan Partners, H&Q Healthcare Investors and H&Q Life Sciences Investors.

Aug

2011

Neuronetics, Inc.: Series E $30M

Posted in I - Series E, Q - 2Q11, R - NORTH EAST, X - Device (Neuromod), X - Device (Neuromodulation), XX - PA

Neuronetics (Malvern, PA) a commercial-stage medical device company focused on pulsed magnetic field stimulation for non-invasive, non-systemic treatment of depression, closed a $30M Series E financing. Participants include Polaris Venture Partners, Pfizer Venture Investments, Investor Growth Capital, New Leaf Venture Partners, Interwest Partners, Three Arch Partners, Quaker BioVentures and Onset Ventures.

Mar

2011

Synageva BioPharma Corp.: Series C $25M

Posted in I - Series C, Q - 1Q11, R - NORTH EAST, X - Lysosomal Storage, X - Metabolism, XX - MA

Synageva BioPharma (Lexington, MA) a clinical-stage biopharma focused on rare diseases and orphan therapeutics for the treatment of lysosomal storage disease and metabolic disorders, closed a $25M Series C financing. Participants have included New Leaf Venture Partners, Hunt BioVentures, Yasuda Enterprise Development, Baker Brothers Investments, Tullis Dickerson and Four Partners.

Feb

2011

Chimerix, Inc.: Series F $45M

Posted in I - Series F, Q - 1Q11, R - SOUTH EAST, X - Antiviral, X - CMV, XX - NC

Chimerix (Durham, NC) a clinical-stage pharma company developing broad spectrum antiviral agents focusing on CMV and BK viruria, closed a $45M Series F financing. Participants include Pappas Ventures, Morningside Group, Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Co., Frazier Healthcare Ventures and New Leaf Venture Partners.

Jan

2011

Pearl Therapeutics, Inc.: Series C $69M

Posted in I - Series C, Q - 4Q10, R - WEST, X - COPD, XX - CA

Pearl Therapeutics (Redwood City, CA) a clinical-stage small molecule company focused on combination therapy for chronic obstructive pulmonary disease, closed a $69M Series C financing. Participants include Vatera Healthcare Partners, Clarus Ventures, New Leaf Venture Partners and 5AM Ventures.

Nov

2010

Convergence Pharmaceuticals, Ltd.: Series A $35.4M

Posted in I - Series A, Q - 4Q10, R - INTERNATIONAL, X - Pain

Convergence Pharmaceuticals (United Kingdom) a clinical-stage small molecule company focused on the treatment of neuropathic and chronic pain, closed a $35.4M Series A financing. Participants include New Leaf Venture Partners, Apposite Capital and SV Life Sciences.

Jun

2010

Altura Medical, Inc.: Series A $20M

Posted in I - Series A, Q - 2Q10, R - WEST, X - Device (Aneurysm), XX - CA

Altura Medical (San Clemente, CA) a development-stage medical device company focused on the treatment of abdominal aortic aneurysms, closed a $20M Series A financing. Participants include New Leaf Venture Partners, Advanced Technology Ventures and SV Life Sciences.

May

2010

Oxford Immunotec, Ltd.: Series D $26M

Posted in I - Series D, Q - 2Q10, R - INTERNATIONAL, X - Device (Diagnostic), X - Tuberculosis

Oxford Immunotec (United Kingdom) a commercial-stage molecular diagnostic company focused on an vitro test for the diagnosis of active and latent tuberculosis infection, closed a $26M Series D financing. Participants include New Leaf Venture Partners, Kaiser Permanente Ventures, Clarus Ventures, Wellington Partners, National Technology Enterprises Company, Spark Ventures, DFJ Esprit, Oxford University and Dow Chemical.

Apr

2010

Aureon Laboratories, Series D: $7M

Posted in I - Series D, Q - 1Q10, R - NORTH EAST, X - Device (Diagnostic), X - Oncology, X - PSA, XX - NY

Aureon Laboratories (New York, NY) a commercial-stage diagnostic company focused on prognostic assays for prostate cancer and PSA, closed a $7M Series D financing. Participants have included Atlas Venture, New Leaf Venture Partners, Sprout Group and Pfizer.

Apr

2010

Tioga Pharmaceuticals, Inc.: Series C $18M

Posted in I - Series C, Q - 1Q10, R - WEST, X - IBS, X - Kappa Opioid, XX - CA

Tioga Pharmaceuticals (San Diego, CA) a clinical-stage small molecule company focused on diarrhea predominant Irritable Bowel Syndrome, closed a $18M Series C financing. Participants include Forward Ventures, New Leaf Venture Partners, BB Biotech Ventures and Genesys Capital.

Mar

2010

Pearl Therapeutics, Inc.: Series B $15M

Posted in I - Series C, Q - 1Q10, R - WEST, X - Asthma, X - COPD, XX - CA

Pearl Therapeutics (Redwood City, CA) a clinical-stage pharma company focused on metered dose inhaler products for the treatment of COPD and asthma, closed a $15M Series C financing. Participants include Clarus Ventures, New Leaf Venture Partners and 5AM Ventures.

Feb

2010

Afferent Pharmaceuticals, Inc.: Series A $23M

Posted in I - Series A, Q - 4Q09, R - WEST, X - Pain, XX - CA

Afferent Pharmaceuticals (Palo Alto, CA) a clinical-stage biopharmaceutical company focused on pain associated with conditions such as osteoarthritis, back pain, visceral pain and neuropathy, closed a $23M Series A financing. Participants include Third Rock Ventures, Pappas Ventures, Domain Associates and New Leaf Venture Partners. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

to top of page...